Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of the acquired immune deficiency syndrome.

Literature DB >> 2424929

Treatment of the acquired immune deficiency syndrome.

Abstract

The acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC) are sequelae of immune system injury initiated by a novel human retrovirus [human T-lymphotrophic virus strain III/lymphadenopathy-associated virus (HTLV III/LAV)]. The resulting spectrum of immune deficiency sets the stage for opportunistic infection and malignancy. In this review, we consider progress made in the treatment and prevention of AIDS and HTLV III/LAV infection. Immunomodulator and antiviral approaches are discussed.

Entities: Disease Species

Mesh：

Substances：

Year: 1986 PMID： 2424929 DOI： 10.1007/bf00918698

Source DB: PubMed Journal: J Clin Immunol ISSN： 0271-9142 Impact factor: 8.317

55 in total

1. Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors: L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal: Nature Date: 1985 Jan 24-30 Impact factor: 49.962

Review 2. The prospects for and pathways toward a vaccine for AIDS.

Authors: D P Francis; J C Petricciani
Journal: N Engl J Med Date: 1985-12-19 Impact factor: 91.245

3. Interaction of vesicular stomatitis virus with lipid vesicles: depletion of cholesterol and effect on virion membrane fluidity and infectivity.

Authors: N F Moore; E J Patzer; J M Shaw; T E Thompson; R R Wagner
Journal: J Virol Date: 1978-08 Impact factor: 5.103

4. Lymphocyte transfusion in case of acquired immunodeficiency syndrome.

Authors: K C Davis; A Hayward; G Oztürk; P F Kohler
Journal: Lancet Date: 1983-03-12 Impact factor: 79.321

5. Inactivation of HTLV-III/LAV-infected cultures of normal human lymphocytes by nonoxynol-9 in vitro.

Authors: D R Hicks; L S Martin; J P Getchell; J L Heath; D P Francis; J S McDougal; J W Curran; B Voeller
Journal: Lancet Date: 1985 Dec 21-28 Impact factor: 79.321

6. Study of activated T cells in man. II. Interleukin 2 receptor and transferrin receptor expression on T cells and production of interleukin 2 in patients with acquired immune deficiency syndrome (AIDS) and AIDS-related complex.

Authors: S Gupta
Journal: Clin Immunol Immunopathol Date: 1986-01

7. Autologous mixed lymphocyte reaction in man. XIV. Deficiency of the autologous mixed lymphocyte reaction in acquired immune deficiency syndrome (AIDS) and AIDS related complex (ARC). In vitro effect of purified interleukin-1 and interleukin-2.

Authors: S Gupta; S Gillis; M Thornton; M Goldberg
Journal: Clin Exp Immunol Date: 1984-11 Impact factor: 4.330

8. Human lymphoblastoid interferon treatment of Kaposi's sarcoma in the acquired immune deficiency syndrome. Clinical response and prognostic parameters.

Authors: E P Gelmann; O T Preble; R Steis; H C Lane; A H Rook; M Wesley; J Jacob; A Fauci; H Masur; D Longo
Journal: Am J Med Date: 1985-05 Impact factor: 4.965

9. Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS.

Authors: H J Alter; J W Eichberg; H Masur; W C Saxinger; R Gallo; A M Macher; H C Lane; A S Fauci
Journal: Science Date: 1984-11-02 Impact factor: 47.728

10. Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism.

Authors: A H Rook; J J Hooks; G V Quinnan; H C Lane; J F Manischewitz; A M Macher; H Masur; A S Fauci; J Y Djeu
Journal: J Immunol Date: 1985-03 Impact factor: 5.422

2 in total

1. Human immunodeficiency virus (HIV) infection for the general physician.

Authors: R J Gilson; I V Weller
Journal: Postgrad Med J Date: 1987-06 Impact factor: 2.401

2. Suramin inhibits tumor cell cytotoxicity mediated through natural killer cells, lymphokine-activated killer cells, monocytes, and tumor necrosis factor.

Authors: R LaPushin; K Totpal; M Higuchi; B B Aggarwal
Journal: J Clin Immunol Date: 1994-01 Impact factor: 8.317

2 in total